Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

SungGi Chi, MD PhD, Naoko Hosono, MD PhD, Takahiro Yamauchi, MD PhD, Kentaro Fukushima, MD, Hirohiko Shibayama, MD PhD, Seiichiro Katagiri, MDPhD, Akihiko Gotoh, MD PhD, Motohito Okabe, MD, Takanobu Morishita, MD, PhD, Masamitsu Yanada, MD PhD, Kazuhito Yamamoto, MD PhD, Naohito Fujishima, MD PhD, Naoto Takahashi, MD PhD, Reiki Ogasawara, MDPhD, Takeshi Kondo, MD PhD, Yoshikazu Utsu, MD PhD, Nobuyuki Aotsuka, MD, Yoshimasa Kamoda, MD, Kensuke Usuki, MD PhD, Kanenari Takemura, MD, Yasuyuki Nagata, MD PhD, Takaaki Ono, MD PhD, Tsutomu Kobayashi, MD PhD, Junya Kuroda, MD PhD, Hiroto Horiguchi, MDPhD, Satoshi Iyama, MD PhD, Suguru Fukuhara, MD PhD, Koji Izutsu, MD PhD, Makoto Nakamura, MD PhD, Kazuto Togitani, MD, Kensuke Kojima, MD PhD, Kaoru Yamamoto, MD, Yukinori Nakamura, MD, Makoto Yoshimitsu, MD PhD, Kenji Ishitsuka, MD PhD, Kenichi Miyamoto, MD, Yosuke Minami, MDPhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139240

Published: 2020

Journal Articles

Prospective Evaluation of Prognostic Relevance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: Results from the JALSG CBF-AML209-KIT Study

Blood (2018) 132 (Supplement 1): 438.

https://doi.org/10.1182/blood-2018-99-113931

Published: 2018

Journal Articles

Effect Of Recombinant Human Soluble Thrombomodulin On Clinical Outcomes Of patients With Coagulopathy After Hematopoietic Stem Cell Transplantation

SungGi Chi, Takayuki Ikezoe, MD. PhD, Asako Takeuchi, Kazuki Anabuki, Tsukie Kim, Mizu Sakai, Ayuko Taniguchi, Kazuto Togitani, Akihito Yokoyama

Blood (2013) 122 (21): 4803.

https://doi.org/10.1182/blood.V122.21.4803.4803

Published: 2013

Journal Articles

Recombinant Human Soluble Thrombomodulin Enhances the Anti-Fibrinolytic and Anti-Leukemia Effects of All- Trans Retinoic Acid In Acute Promyelocytic Leukemia Cells.

Takayuki Ikezoe, Jing Yang, Chie Nishioka, Mayuka Isaka, Naomi Iwabu, Mizu Sakai, Ayuko Taniguchi, Kazuto Togitani, Goichi Honda, Akihito Yokoyama

Blood (2010) 116 (21): 1079.

https://doi.org/10.1182/blood.V116.21.1079.1079

Published: 2010

Journal Articles

Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo

Chie Nishioka, Takayuki Ikezoe, Jing Yang, Atsushi Miwa, Taizo Tasaka, Yoshio Kuwayama, Kazuto Togitani, H. Phillip Koeffler, Akihito Yokoyama

Blood (2008) 111 (10): 5086–5092.

https://doi.org/10.1182/blood-2007-06-098079

Published: 2008

Includes: Supplemental data

Journal Articles

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

Jing Yang, Takayuki Ikezoe, Chie Nishioka, Taizo Tasaka, Ayuko Taniguchi, Yoshio Kuwayama, Naoki Komatsu, Kentaro Bandobashi, Kazuto Togitani, H. Phillip Koeffler, Hirokuni Taguchi, Akihito Yokoyama

Blood (2007) 110 (6): 2034–2040.

https://doi.org/10.1182/blood-2007-02-073700

Published: 2007

Journal Articles

ZM447439, a Novel Aurora Kinase Inhibitor, Induces Growth Arrest and Apoptosis of Human Leukemia Cells.

Takayuki Ikezoe, MD, Chie Nishioka, Taizo Tasaka, MD, Ayuko Taniguchi, MD, Naoki Komatsu, MD, Yoshio Kuwayama, MD, Kazuto Togitani, MD, H. Phillip Koeffler, MD, Hirokuni Taguchi, MD

Blood (2006) 108 (11): 1990.

https://doi.org/10.1182/blood.V108.11.1990.1990

Published: 2006

Journal Articles

Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) in Japan: An Analysis from West-Japan Hematology/Oncology Group (West-JHOG) NHL Outcomes Project.

Blood (2006) 108 (11): 4698.

https://doi.org/10.1182/blood.V108.11.4698.4698

Published: 2006

Journal Articles

The Anti-Tumor Effects of SU11248, a Class III Receptor Tyrosine Kinase Inhibitor, Against a Variety of Human Hematological Malignancies.

Takayuki Ikezoe, MD, Kentaro Bandobashi, MD, Yang Yang, Tsuyako Saito, MD, Kazuto Togitani, MD, Taizo Tasaka, MD, H. Phillip Koeffler, MD, Hirokuni Taguchi, MD

Blood (2005) 106 (11): 2795.

https://doi.org/10.1182/blood.V106.11.2795.2795

Published: 2005

NARROW

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

Prospective Evaluation of Prognostic Relevance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: Results from the JALSG CBF-AML209-KIT Study

Effect Of Recombinant Human Soluble Thrombomodulin On Clinical Outcomes Of patients With Coagulopathy After Hematopoietic Stem Cell Transplantation

Recombinant Human Soluble Thrombomodulin Enhances the Anti-Fibrinolytic and Anti-Leukemia Effects of All- Trans Retinoic Acid In Acute Promyelocytic Leukemia Cells.

Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

ZM447439, a Novel Aurora Kinase Inhibitor, Induces Growth Arrest and Apoptosis of Human Leukemia Cells.

Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) in Japan: An Analysis from West-Japan Hematology/Oncology Group (West-JHOG) NHL Outcomes Project.

The Anti-Tumor Effects of SU11248, a Class III Receptor Tyrosine Kinase Inhibitor, Against a Variety of Human Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only